Literature DB >> 31113567

Epidemiology of massive hepatocellular carcinoma in dogs: A 4-year retrospective study.

R Leela-Arporn1, H Ohta1, N Nagata1, K Sasaoka1, M Tamura1, A Dermlim1, K Nisa1, K Morishita2, N Sasaki1, K Nakamura2, S Takagi2, K Hosoya2, M Takiguchi3.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver tumour in dogs. However, the clinical features and risk factors of HCC have not been confirmed. The objective of this study was to investigate the clinical features and risk factors for canine HCC. Medical records of 44 dogs diagnosed with HCC at Hokkaido University Veterinary Teaching Hospital between 2013 and 2017 were retrospectively reviewed. All dogs evaluated at the teaching hospital during the study period were used as the reference population for breed, age, sex predispositions or possible related factors for HCC, including concurrent disorders. Clinical characteristics of HCC were determined using propensity score matching analysis. The prevalence of HCC diagnosis was 0.96%. Multivariate analysis revealed that dogs diagnosed with HCC were significantly older (odds ratio [OR], 1.20; 95% confidence intervals [CI], 1.07-1.33) than the reference population. Welsh Corgis (OR, 3.68; 95% CI, 1.56-8.67) and Beagles (OR, 4.33; 95% CI, 1.58-11.90) were significantly predisposed to HCC. Twenty-seven of 44 dogs with HCC had at least one concurrent disorder. The most common concurrent disorder was hyperadrenocorticism (n = 10), and the adjusted odds of hyperadrenocorticism in dogs with HCC were 4.13 higher than those of the reference population (95% CI, 1.95-8.76). Propensity score matching analysis revealed that thrombocytosis (n = 30/43), increased alanine aminotransferase (n = 41/44), increased alkaline phosphatase (n = 42/44), and hypercalcemia (n = 13/32) were significantly associated with HCC diagnosis. The results of this study suggest that Welsh Corgis and Beagles are breeds with a predisposition for HCC and that hyperadrenocorticism might be a potential risk factor.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Canine; Hepatocellular carcinoma; Hyperadrenocorticism; Risk factors

Mesh:

Year:  2019        PMID: 31113567     DOI: 10.1016/j.tvjl.2019.04.011

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  3 in total

1.  Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case-control study.

Authors:  Janis M Lapsley; Vincent Wavreille; Sabrina Barry; Josephine A Dornbusch; Carolyn Chen; Haley Leeper; Judith Bertran; Diane Scavelli; Julius M Liptak; Chris Wood; Shelly Shamir; Claire Rosenbaum; Vincenzo Montinaro; Brandan Wustefeld-Janssens; Allyson Sterman; Colin Chik; Ameet Singh; Josh Collins; Laura E Selmic
Journal:  Vet Comp Oncol       Date:  2022-05-15       Impact factor: 2.385

2.  Comparison of median sternotomy closure-related complication rates using orthopedic wire or suture in dogs: A multi-institutional observational treatment effect analysis.

Authors:  Mariette A Pilot; Aaron Lutchman; Julie Hennet; Davina Anderson; William Robinson; Matteo Rossanese; Angelos Chrysopoulos; Jackie Demetriou; Benito De la Puerta; Ronan A Mullins; Hervé Brissot; Nicholas Jeffery; Guillaume Chanoit
Journal:  Vet Surg       Date:  2022-06-28       Impact factor: 1.618

3.  Serum steroid profiling of hepatocellular carcinoma associated with hyperadrenocorticism in dogs: A preliminary study.

Authors:  Thandar Oo; Noboru Sasaki; Yoshinori Ikenaka; Takahiro Ichise; Noriyuki Nagata; Nozomu Yokoyama; Kazuyoshi Sasaoka; Keitaro Morishita; Kensuke Nakamura; Mitsuyoshi Takiguchi
Journal:  Front Vet Sci       Date:  2022-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.